carboplatin + pemetrexed + zimberelimab

This is a combination regimen consisting of three agents: - **Carboplatin** (a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells) - **Pemetrexed** (an antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes involved in the synthesis of nucleotides, thereby blocking DNA and RNA synthesis) - **Zimberelimab** (a humanized monoclonal antibody targeting programmed cell death protein 1 [PD-1], functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses). This combination is being investigated primarily for the first-line treatment of metastatic non-small cell lung cancer (NSCLC), particularly in patients with non-squamous histology and no actionable genomic alterations. The regimen leverages both cytotoxic chemotherapy and immunotherapy to improve clinical outcomes[2][4][5].

Brand names

ParaplatinAlimta

Other names

zimberelimab + carboplatin + pemetrexed